• Topic of the Month
  • Disease Risk Reduction
  • Vitamin E
  • Deficiency
  • Vitamin D
  • B Vitamins
  • Beta-Carotene
  • Health Functions
  • Vitamin A
  • Carotenoids
  • 2017

How Our Genes Affect Our Micronutrient Needs

Published on

31 March 2017

By Julia Bird

Incredible advances in human genome sequencing over the last fifteen years have decreased the cost of finding out the story of our genes to a level that is affordable for the general population, as well as scientists. This has opened the door to personalized medicine and nutrigenetics, which use information about genetics to guide medical therapy or nutritional advice. While this area of research is still in an early phase, and focused on macronutrients, evidence is growing that suggests our genes can affect micronutrient requirements as well.

Folate, genes and neural tube defects

The relationship between folate and neural tube defects is well known. Women who are planning a pregnancy are advised to consume adequate folic acid to avoid neural tube defects (Viswanathan, 2017). Half the cases of neural tube defects are estimated to be caused by low folic acid levels, however this is only part of the tale. Blood folate levels are related to not only diet but also genetics. In particular, differences in the MTHFR (methylenetetrahydrofolate reductase) enzyme, caused by slight genetic variations, lead to clear changes in blood levels of folate (Tsang, 2015).

The MTHFR enzyme is responsible for converting dietary folate into the active form that is used in the body. The 677TT variant of the gene results in an enzyme that is more likely to break down in response to heat than the normal 677CC variant, and is less stable in general, thus circulating folate concentrations are lower (Molloy, 1997). While supplementation with folic acid is able to improve folate status regardless of genes, the effect in people with the 677TT variant is much smaller than for those with the other genetic variants (Cabo, 2015). Yan and co-workers (2012) report that women with the TT variant had double the risk of having a pregnancy affected by a neural tube defect, compared to the CC variant. It seems likely that women with the 677TT variant should pay close attention to their folate intake and status. In future, we may see changes in folic acid recommendations based on MTHFR variant if genetic testing becomes more commonplace.

The genetics of converting beta-carotene to vitamin A

Beta-carotene – found in orange, yellow and dark green fruits and vegetables – is a major source of vitamin A in people’s diets. For people who do not eat animal-based products, it is the only way they get enough vitamin A from their foods. Beta-carotene is considered a pro-vitamin because it must first be converted to vitamin A before it can be used by the body. The first step in this conversion process happens in the intestines. An enzyme produced by cells in the intestinal lining, β,β-carotene-15,15′-monooxygenase, cuts beta-carotene in two. The result is two molecules of retinal, a form of vitamin A. This enzyme is also able to convert the other pro-vitamin A carotenoids, beta-cryptoxantin and apocarotenal, to vitamin A as well. 

Variations in the gene that produces the beta-carotene conversion enzyme, BCMO1, affect vitamin A status and levels of carotenoids in the body. If the enzyme does not work well, carotenoid levels in the body tend to increase while vitamin A levels remain low. For example, some families are prone to an orange color forming in their skin despite a normal diet, and may show signs of vitamin A deficiency (Sharvill, 1970). A small change in the gene responsible for BCMO1 produces an enzyme with only 10 percent of the activity of the normal gene (Lindqvist, 2007), which means that beta-carotene is absorbed but not converted to vitamin A, leading to excessive levels in the skin and the potential for vitamin A deficiency. Other studies have found more subtle, yet still significant, effects of small genetic variations on beta-carotene conversion to vitamin A. For example, several genetic variations in the DNA close to the BCMO1 gene mean that it works about half as well as it should, and this also results in a much lower vitamin A level (Lietz, 2012). Likewise, another small change within the BCMO1 gene sequence results in an enzyme that has a lower activity than normal, and circulating beta-carotene concentrations were considerably higher (Hendrickson, 2012). People with a poorly functioning version of the BCMO1 gene have a higher risk of vitamin A deficiency and must ensure their diets include a source of vitamin A other than fruits and vegetables.

Riboflavin and hypertension – do genes decide who needs more?

The importance of a balanced diet can be seen with the B-vitamins – four all contribute together to DNA synthesis and the metabolism of amino acids. Riboflavin in particular is considered to be an “active co-factor” in the conversion of dietary folate to its active form, and helps vitamin B6 to remove the undesirable amino acid homocysteine from the body (McMahon, 2016). For people with the 677TT variant of the MTHFR enzyme, as discussed above in the folate example, riboflavin may be particularly important. These people have lower circulating levels of folate and elevated levels of homocysteine in the blood. They also have a greater risk of cardiovascular disease, partly due to their higher blood pressure (Wilson, 2012). It seems that the poorly functioning 677TT variant of the MTHFR enzyme can be stabilized by an adequate riboflavin status. Improvements in blood pressure are thought to come from the resulting increase in active folate in the body, which helps blood vessels to widen (McMahon, 2016).

Preliminary clinical trials have looked at the effect of riboflavin supplementation in people with the 677TT variant of the MTHFR enzyme. In the first trial, patients with premature cardiovascular disease were screened for the MTHFR 677C→T variant and then randomized to 1.6 mg riboflavin daily or a placebo for two months. The dose used is close to the recommended intake for adults. The same supplementation strategy was performed in the same patient group four years later, however treatment groups were reversed. After two months of riboflavin supplementation at both time points, blood pressure decreased significantly, but only in adults with the 677TT genetic variant (Wilson, 2012). The same research group conducted a second study in patients with the 677TT genotype only. After four months of taking 4.6 mg per day of riboflavin, the subjects had a significant reduction in their systolic blood pressure (Wilson, 2013). These two studies have tested a nutritionally obtainable dose of riboflavin to produce a small reduction in blood pressure. Research is ongoing to determine whether a higher dose can further reduce blood pressure in the RIBOGENE study. 

Future directions in nutrigenetics

As genetic testing becomes more commonplace, the ease of conducting nutrigenetic research will increase. Other micronutrients that are being investigated include:

  • Vitamin B6 (Carter, 2015)
  • Vitamin B12 (Tanner, 2012)
  • Vitamin C (Shaghaghi, 2016)
  • Vitamin D (Desmarchelier, 2016)
  • Vitamin E (Borel, 2016)

Breakthroughs in the understanding of how our genes and diet interact to affect our health and nutrient requirements are slowly changing the field of nutrition. While it is too soon to be able to prescribe a particular diet based on genetic testing, in the future we may see personalized nutrition plans emerge to complement general diet and lifestyle advice that will maximize the effect that nutrition has on our health.


  1. Borel P, Desmarchelier C. Genetic Variations Involved in Vitamin E Status. Int J Mol Sci. 2016 Dec 13;17(12). pii: E2094.
  2. Cabo R, Hernes S, Slettan A, Haugen M, Ye S, Blomhoff R, Mansoor MA. Effect of genetic polymorphisms involved in folate metabolism on the concentration of serum folate and plasma total homocysteine (p-tHcy) in healthy subjects after short-term folic acid supplementation: a randomized, double blind, crossover study. Genes Nutr. 2015 May;10(3):456. doi: 10.1007/s12263-015-0456-4. Epub 2015 Mar 11.
  3. Carter TC, Pangilinan F, Molloy AM, Fan R, Wang Y, Shane B, Gibney ER, Midttun Ø, Ueland PM, Cropp CD, Kim Y, Wilson AF, Bailey-Wilson JE, Brody LC, Mills JL. Common Variants at Putative Regulatory Sites of the Tissue Nonspecific Alkaline Phosphatase Gene Influence Circulating Pyridoxal 5'-Phosphate Concentration in Healthy Adults. J Nutr. 2015 Jul;145(7):1386-93. doi: 10.3945/jn.114.208769. Epub 2015 May 13.
  4. Desmarchelier C, Borel P, Goncalves A, Kopec R, Nowicki M, Morange S, Lesavre N, Portugal H, Reboul E. A Combination of Single-Nucleotide Polymorphisms Is Associated with Interindividual Variability in Cholecalciferol Bioavailability in Healthy Men. J Nutr. 2016 Dec;146(12):2421-2428. Epub 2016 Oct 26.
  5. Hendrickson SJ, Hazra A, Chen C, Eliassen AH, Kraft P, Rosner BA, Willett WC. β-Carotene 15,15'-monooxygenase 1 single nucleotide polymorphisms in relation to plasma carotenoid and retinol concentrations in women of European descent. Am J Clin Nutr. 2012 Dec;96(6):1379-89. doi: 10.3945/ajcn.112.034934. Epub 2012 Nov 7.
  6. Lietz G, Oxley A, Leung W, Hesketh J. Single nucleotide polymorphisms upstream from the β-carotene 15,15'-monoxygenase gene influence provitamin A conversion efficiency in female volunteers. J Nutr. 2012 Jan;142(1):161S-5S. doi: 10.3945/jn.111.140756. Epub 2011 Nov 23.
  7. Lindqvist A, Sharvill J, Sharvill DE, Andersson S. Loss-of-function mutation in carotenoid 15,15'-monooxygenase identified in a patient with hypercarotenemia and hypovitaminosis A. J Nutr. 2007 Nov;137(11):2346-50.
  8. McMahon A, McNulty H, Hughes CF, Strain JJ, Ward M. Novel Approaches to Investigate One-Carbon Metabolism and Related B-Vitamins in Blood Pressure. Nutrients. 2016 Nov 11;8(11). pii: E720.
  9. Molloy AM, Daly S, Mills JL, Kirke PN, Whitehead AS, Ramsbottom D, Conley MR, Weir DG, Scott JM. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet. 1997 May 31;349(9065):1591-3.
  10. Powers HJ, Hill MH, Mushtaq S, Dainty JR, Majsak-Newman G, Williams EA. Correcting a marginal riboflavin deficiency improves hematologic status in young women in the United Kingdom (RIBOFEM). Am J Clin Nutr. 2011 Jun;93(6):1274-84. doi: 10.3945/ajcn.110.008409. Epub 2011 Apr 27.
  11. Shaghaghi MA, Kloss O, Eck P. Genetic Variation in Human Vitamin C Transporter Genes in Common Complex Diseases. Adv Nutr. 2016 Mar 15;7(2):287-98. doi: 10.3945/an.115.009225. Print 2016 Mar.
  12. Sharvill DE. Familial hypercarotinaemia and hypovitaminosis A. Proc R Soc Med. 1970 Jun;63(6):605-6.
  13. Tanner SM, Sturm AC, Baack EC, Liyanarachchi S, de la Chapelle A. Inherited cobalamin malabsorption. Mutations in three genes reveal functional and ethnic patterns. Orphanet J Rare Dis. 2012 Aug 28;7:56. doi: 10.1186/1750-1172-7-56.
  14. Tsang BL, Devine OJ, Cordero AM, Marchetta CM, Mulinare J, Mersereau P, Guo J, Qi YP, Berry RJ, Rosenthal J, Crider KS, Hamner HC. Assessing the association between the methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism and blood folate concentrations: a systematic review and meta-analysis of trials and observational studies. Am J Clin Nutr. 2015 Jun;101(6):1286-94. doi: 10.3945/ajcn.114.099994. Epub 2015 Mar 18.
  15. Viswanathan M, Treiman KA, Doto JK, Middleton JC, Coker-Schwimmer EJL, Nicholson WK. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Folic Acid Supplementation: An Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Jan. Report No.: 14-05214-EF-1.
  16. Wilson CP, McNulty H, Ward M, Strain JJ, Trouton TG, Hoeft BA, Weber P, Roos FF, Horigan G, McAnena L, Scott JM. Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial. Hypertension. 2013 Jun;61(6):1302-8. doi: 10.1161/HYPERTENSIONAHA.111.01047. Epub 2013 Apr 22.
  17. Wilson CP, Ward M, McNulty H, Strain JJ, Trouton TG, Horigan G, Purvis J, Scott JM. Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up. Am J Clin Nutr. 2012 Mar;95(3):766-72. doi: 10.3945/ajcn.111.026245. Epub 2012 Jan 25.
  18. Yan L, Zhao L, Long Y, Zou P, Ji G, Gu A, Zhao P. Association of the maternal MTHFR C677T polymorphism with susceptibility to neural tube defects in offsprings: evidence from 25 case-control studies. PLoS One. 2012;7(10):e41689. doi: 10.1371/journal.pone.0041689. Epub 2012 Oct 3.

This site uses cookies to store information on your computer.

Learn more